Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Female participants, \>/= 18 years of age
Metastatic breast cancer
Estrogen receptor-, progesterone- and human epidermal growth factor receptor 2 (HER2)-negative disease
Treatment-naïve for metastatic breast cancer
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Adequate hematological, renal and liver function
Patients should have received Anthracyclines and Taxanes in the adjuvant setting
Women of childbearing potential must agree to use adequate contraception (per institutional standard of care) during treatment and until 6 months after the last administration of investigational products
You may not be if
Prior first line treatment for metastatic breast cancer
Central nervous system (CNS) metastasis
Uncontrolled hypertension (\> 170/95 mmHg)
Evidence of bleeding diathesis, coagulopathy or hemorrhage at baseline
Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer.
Prior therapy with gemcitabine or carboplatin in the metastatic setting. Participants having received gemcitabine or carboplatin as part of adjuvant therapy are eligible, if recurrence was first documented \>6 months after the last exposure to the drug(s)
Requirement of chronic use of immunosuppressive agents
HIV, hepatitis B or hepatitis C infection
Clareo Health | A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer
